Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.50 | N/A | +12.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.50 | N/A | +12.16% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in the company's current trajectory while emphasizing the importance of innovation. They are committed to enhancing their product offerings.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in R&D to drive future growth.
Focus remains on expanding market access for existing products.
Eli Lilly's earnings report shows a solid EPS beat, indicating better-than-expected profitability. However, the lack of revenue data and guidance may leave investors cautious. The stock reaction is not available, but the strong EPS performance suggests underlying strength in the business.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 23, 2018